207 related articles for article (PubMed ID: 29736778)
1. Effects of polymorphisms in NR1I2, CYP3A4, and ABC transporters on the steady-state plasma trough concentrations of bosutinib in Japanese patient with chronic myeloid leukemia.
Abumiya M; Mita A; Takahashi S; Yoshioka T; Kameoka Y; Takahashi N; Miura M
Med Oncol; 2018 May; 35(6):90. PubMed ID: 29736778
[TBL] [Abstract][Full Text] [Related]
2. Influence of CYP3A4/5 and ABC transporter polymorphisms on lenvatinib plasma trough concentrations in Japanese patients with thyroid cancer.
Ozeki T; Nagahama M; Fujita K; Suzuki A; Sugino K; Ito K; Miura M
Sci Rep; 2019 Apr; 9(1):5404. PubMed ID: 30931962
[TBL] [Abstract][Full Text] [Related]
3. Effects of SLC22A2 808G>T polymorphism and bosutinib concentrations on serum creatinine in patients with chronic myeloid leukemia receiving bosutinib therapy.
Abumiya M; Takahashi N; Takahashi S; Yoshioka T; Kameoka Y; Miura M
Sci Rep; 2021 Mar; 11(1):6362. PubMed ID: 33737618
[TBL] [Abstract][Full Text] [Related]
4. CYP3A5*3 and ABCB1 61A>G Significantly Influence Dose-adjusted Trough Blood Tacrolimus Concentrations in the First Three Months Post-Kidney Transplantation.
Hu R; Barratt DT; Coller JK; Sallustio BC; Somogyi AA
Basic Clin Pharmacol Toxicol; 2018 Sep; 123(3):320-326. PubMed ID: 29603629
[TBL] [Abstract][Full Text] [Related]
5. Long-Term Influence of CYP3A5, CYP3A4, ABCB1, and NR1I2 Polymorphisms on Tacrolimus Concentration in Chinese Renal Transplant Recipients.
Liu F; Ou YM; Yu AR; Xiong L; Xin HW
Genet Test Mol Biomarkers; 2017 Nov; 21(11):663-673. PubMed ID: 28945481
[TBL] [Abstract][Full Text] [Related]
6. Impacts of pregnane X receptor and cytochrome P450 oxidoreductase gene polymorphisms on trough concentrations of apixaban in patients with non-valvular atrial fibrillation.
Nakagawa J; Kinjo T; Aiuchi N; Ueno K; Tomita H; Niioka T
Eur J Clin Pharmacol; 2023 Jan; 79(1):127-135. PubMed ID: 36399204
[TBL] [Abstract][Full Text] [Related]
7. Associations of ABCB1, NFKB1, CYP3A, and NR1I2 polymorphisms with cyclosporine trough concentrations in Chinese renal transplant recipients.
Zhang Y; Li JL; Fu Q; Wang XD; Liu LS; Wang CX; Xie W; Chen ZJ; Shu WY; Huang M
Acta Pharmacol Sin; 2013 Apr; 34(4):555-60. PubMed ID: 23503472
[TBL] [Abstract][Full Text] [Related]
8. Effects of polymorphisms in pregnane X receptor and ABC transporters on afatinib in Japanese patients with non-small cell lung cancer: pharmacogenomic-pharmacokinetic and exposure-response analysis.
Yokota H; Sato K; Sakamoto S; Okuda Y; Asano M; Takeda M; Nakayama K; Miura M
Cancer Chemother Pharmacol; 2023 Oct; 92(4):315-324. PubMed ID: 37500985
[TBL] [Abstract][Full Text] [Related]
9. Interactive effects of CYP3A4, CYP3A5, MDR1 and NR1I2 polymorphisms on tracrolimus trough concentrations in early postrenal transplant recipients.
Li JL; Liu S; Fu Q; Zhang Y; Wang XD; Liu XM; Liu LS; Wang CX; Huang M
Pharmacogenomics; 2015; 16(12):1355-65. PubMed ID: 26228923
[TBL] [Abstract][Full Text] [Related]
10. Effect of tacrolimus dispositional genetics on acute rejection in the first 2 weeks and estimated glomerular filtration rate in the first 3 months following kidney transplantation.
Hu R; Barratt DT; Coller JK; Sallustio BC; Somogyi AA
Pharmacogenet Genomics; 2019 Jan; 29(1):9-17. PubMed ID: 30489455
[TBL] [Abstract][Full Text] [Related]
11. The impact of genetic polymorphisms, diltiazem, and demographic variables on everolimus trough concentrations in lung transplant recipients.
Schoeppler KE; Aquilante CL; Kiser TH; Fish DN; Zamora MR
Clin Transplant; 2014 May; 28(5):590-7. PubMed ID: 24628014
[TBL] [Abstract][Full Text] [Related]
12. Effects of
Yagishita H; Kagaya H; Saito M; Numakura K; Yamamoto R; Sagehashi R; Habuchi T; Satoh S; Miura M
Int J Mol Sci; 2022 Oct; 23(19):. PubMed ID: 36233042
[TBL] [Abstract][Full Text] [Related]
13. Quantification of the steady-state plasma concentrations of clozapine and N-desmethylclozapine in Japanese patients with schizophrenia using a novel HPLC method and the effects of CYPs and ABC transporters polymorphisms.
Akamine Y; Sugawara-Kikuchi Y; Uno T; Shimizu T; Miura M
Ann Clin Biochem; 2017 Nov; 54(6):677-685. PubMed ID: 27932669
[TBL] [Abstract][Full Text] [Related]
14. Influence of enzyme and transporter polymorphisms on trough imatinib concentration and clinical response in chronic myeloid leukemia patients.
Seong SJ; Lim M; Sohn SK; Moon JH; Oh SJ; Kim BS; Ryoo HM; Chung JS; Joo YD; Bang SM; Jung CW; Kim DH; Park SY; Yoon SS; Kim I; Lee HG; Won JH; Min YH; Cheong JW; Park JS; Eom KS; Hyun MS; Kim MK; Kim H; Park MR; Park J; Kim CS; Kim HJ; Kim YK; Park EK; Zang DY; Jo DY; Lee HW; Yoon YR
Ann Oncol; 2013 Mar; 24(3):756-60. PubMed ID: 23117072
[TBL] [Abstract][Full Text] [Related]
15. Association of genetic polymorphisms in the influx transporter SLCO1B3 and the efflux transporter ABCB1 with imatinib pharmacokinetics in patients with chronic myeloid leukemia.
Yamakawa Y; Hamada A; Nakashima R; Yuki M; Hirayama C; Kawaguchi T; Saito H
Ther Drug Monit; 2011 Apr; 33(2):244-50. PubMed ID: 21311410
[TBL] [Abstract][Full Text] [Related]
16. Impact of ABCB1, ABCG2, and CYP3A5 polymorphisms on plasma trough concentrations of apixaban in Japanese patients with atrial fibrillation.
Ueshima S; Hira D; Fujii R; Kimura Y; Tomitsuka C; Yamane T; Tabuchi Y; Ozawa T; Itoh H; Horie M; Terada T; Katsura T
Pharmacogenet Genomics; 2017 Sep; 27(9):329-336. PubMed ID: 28678049
[TBL] [Abstract][Full Text] [Related]
17. Population pharmacokinetic modeling of the association between 63396C->T pregnane X receptor polymorphism and unboosted atazanavir clearance.
Schipani A; Siccardi M; D'Avolio A; Baietto L; Simiele M; Bonora S; Rodríguez Novoa S; Cuenca L; Soriano V; Chierakul N; Saguenwong N; Chuchuttaworn C; Hoskins JM; Dvorak AM; McLeod HL; Davies G; Khoo S; Back DJ; Di Perri G; Owen A
Antimicrob Agents Chemother; 2010 Dec; 54(12):5242-50. PubMed ID: 20921307
[TBL] [Abstract][Full Text] [Related]
18. Influence of genetic polymorphisms on imatinib concentration and therapeutic response in patients with chronic-phase chronic myeloid leukemia.
Cheng F; Cui Z; Li Q; Chen S; Li W; Zhang Y
Int Immunopharmacol; 2024 May; 133():112090. PubMed ID: 38640718
[TBL] [Abstract][Full Text] [Related]
19. Single-nucleotide polymorphisms of ABCG2 increase the efficacy of tyrosine kinase inhibitors in the K562 chronic myeloid leukemia cell line.
Skoglund K; Boiso Moreno S; Jönsson JI; Vikingsson S; Carlsson B; Gréen H
Pharmacogenet Genomics; 2014 Jan; 24(1):52-61. PubMed ID: 24322003
[TBL] [Abstract][Full Text] [Related]
20. Effects of Polymorphisms in NR1H4, NR1I2, SLCO1B1, and ABCG2 on the Pharmacokinetics of Rosuvastatin in Healthy Chinese Volunteers.
Liu M; Wu XJ; Zhao GL; Zhang T; Xu SS; Sun YX; Qiu F; Zhao LM
J Cardiovasc Pharmacol; 2016 Nov; 68(5):383-390. PubMed ID: 27557342
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
